Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Excisional surgery versus imiquimod for nodular and superficial basal cell carcinoma
ISRCTN48755084Phase 3Completed
- Sponsor
- University of Nottingham
- Start
- Jun 2003
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of imiquimod in basal cell carcinoma (BCC) (2 arms), sponsored by University of Nottingham. Primary endpoint: Clinical success at 3 years. Started Jun 2003; status: completed.
02
Drugs
imiquimod
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on ISRCTN48755084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN48755084.